Catalent Inc (CTLT) Stock Fundamental Analysis
USA - NYSE:CTLT - US1488061029 - Common Stock
63.48 USD
0 (0%)
63.5 USD
+0.02 (+0.03%)
Taking everything into account, CTLT scores 3 out of 10 in our fundamental rating. CTLT was compared to 196 industry peers in the Pharmaceuticals industry. CTLT has a bad profitability rating. Also its financial health evaluation is rather negative. CTLT has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
CTLT had positive earnings in the past year.
In the past year CTLT had a positive cash flow from operations.
In multiple years CTLT reported negative net income over the last 5 years.
In the past 5 years CTLT always reported a positive cash flow from operatings.
1.2 Ratios
CTLT has a Return On Assets of -4.25%. This is in the better half of the industry: CTLT outperforms 78.01% of its industry peers.
CTLT's Return On Equity of -11.66% is fine compared to the rest of the industry. CTLT outperforms 75.92% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.25% | ||
| ROE | -11.66% | ||
| ROIC | N/A |
ROA(3y)-2.82%
ROA(5y)-0.09%
ROE(3y)-8.14%
ROE(5y)-1.42%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CTLT has a Gross Margin of 21.82%. This is comparable to the rest of the industry: CTLT outperforms 51.83% of its industry peers.
CTLT's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for CTLT so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 21.82% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-13.68%
GM growth 5Y-7.41%
2. Health
2.1 Basic Checks
CTLT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CTLT has more shares outstanding
Compared to 5 years ago, CTLT has more shares outstanding
The debt/assets ratio for CTLT is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of 1.62, we must say that CTLT is in the distress zone and has some risk of bankruptcy.
CTLT has a Altman-Z score of 1.62. This is in the better half of the industry: CTLT outperforms 64.92% of its industry peers.
The Debt to FCF ratio of CTLT is 49.84, which is on the high side as it means it would take CTLT, 49.84 years of fcf income to pay off all of its debts.
CTLT has a better Debt to FCF ratio (49.84) than 78.01% of its industry peers.
A Debt/Equity ratio of 1.38 is on the high side and indicates that CTLT has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 1.38, CTLT is doing worse than 74.87% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.38 | ||
| Debt/FCF | 49.84 | ||
| Altman-Z | 1.62 |
ROIC/WACCN/A
WACC9.31%
2.3 Liquidity
A Current Ratio of 2.51 indicates that CTLT has no problem at all paying its short term obligations.
The Current ratio of CTLT (2.51) is comparable to the rest of the industry.
CTLT has a Quick Ratio of 1.93. This is a normal value and indicates that CTLT is financially healthy and should not expect problems in meeting its short term obligations.
CTLT has a Quick ratio (1.93) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.51 | ||
| Quick Ratio | 1.93 |
3. Growth
3.1 Past
The earnings per share for CTLT have decreased strongly by -61.40% in the last year.
The earnings per share for CTLT have been decreasing by -33.48% on average. This is quite bad
CTLT shows a small growth in Revenue. In the last year, the Revenue has grown by 4.71%.
CTLT shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.71% yearly.
EPS 1Y (TTM)-61.4%
EPS 3Y-56.51%
EPS 5Y-33.48%
EPS Q2Q%-30%
Revenue 1Y (TTM)4.71%
Revenue growth 3Y3.1%
Revenue growth 5Y11.71%
Sales Q2Q%4.18%
3.2 Future
The Earnings Per Share is expected to grow by 73.38% on average over the next years. This is a very strong growth
CTLT is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.44% yearly.
EPS Next Y350.55%
EPS Next 2Y148.11%
EPS Next 3Y113.64%
EPS Next 5Y73.38%
Revenue Next Year8.33%
Revenue Next 2Y8.2%
Revenue Next 3Y8.33%
Revenue Next 5Y7.44%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 288.55, which means the current valuation is very expensive for CTLT.
Compared to the rest of the industry, the Price/Earnings ratio of CTLT indicates a somewhat cheap valuation: CTLT is cheaper than 78.01% of the companies listed in the same industry.
CTLT's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 27.38.
A Price/Forward Earnings ratio of 41.25 indicates a quite expensive valuation of CTLT.
76.44% of the companies in the same industry are more expensive than CTLT, based on the Price/Forward Earnings ratio.
CTLT is valuated expensively when we compare the Price/Forward Earnings ratio to 22.86, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 288.55 | ||
| Fwd PE | 41.25 |
4.2 Price Multiples
76.96% of the companies in the same industry are more expensive than CTLT, based on the Enterprise Value to EBITDA ratio.
78.53% of the companies in the same industry are more expensive than CTLT, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 116.39 | ||
| EV/EBITDA | 36.47 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as CTLT's earnings are expected to grow with 113.64% in the coming years.
PEG (NY)0.82
PEG (5Y)N/A
EPS Next 2Y148.11%
EPS Next 3Y113.64%
5. Dividend
5.1 Amount
No dividends for CTLT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
63.48
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners92.2%
Inst Owner Change-8.79%
Ins Owners0.48%
Ins Owner Change0%
Market Cap11.52B
Analysts52.86
Price Target64.77 (2.03%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-149.78%
Min EPS beat(2)-336.02%
Max EPS beat(2)36.46%
EPS beat(4)1
Avg EPS beat(4)-365.14%
Min EPS beat(4)-1032.86%
Max EPS beat(4)36.46%
EPS beat(8)2
Avg EPS beat(8)-208.81%
EPS beat(12)5
Avg EPS beat(12)-141.22%
EPS beat(16)9
Avg EPS beat(16)-103.51%
Revenue beat(2)1
Avg Revenue beat(2)-0.51%
Min Revenue beat(2)-5.19%
Max Revenue beat(2)4.16%
Revenue beat(4)1
Avg Revenue beat(4)-1.79%
Min Revenue beat(4)-6.04%
Max Revenue beat(4)4.16%
Revenue beat(8)4
Avg Revenue beat(8)0.21%
Revenue beat(12)6
Avg Revenue beat(12)-0.33%
Revenue beat(16)8
Avg Revenue beat(16)-0.03%
PT rev (1m)0.11%
PT rev (3m)4.53%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-43.12%
EPS NY rev (1m)4.18%
EPS NY rev (3m)-6.02%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.9%
Revenue NY rev (1m)-0.08%
Revenue NY rev (3m)-0.69%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 288.55 | ||
| Fwd PE | 41.25 | ||
| P/S | 2.61 | ||
| P/FCF | 116.39 | ||
| P/OCF | 28.88 | ||
| P/B | 3.25 | ||
| P/tB | 31.57 | ||
| EV/EBITDA | 36.47 |
EPS(TTM)0.22
EY0.35%
EPS(NY)1.54
Fwd EY2.42%
FCF(TTM)0.55
FCFY0.86%
OCF(TTM)2.2
OCFY3.46%
SpS24.36
BVpS19.51
TBVpS2.01
PEG (NY)0.82
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.25% | ||
| ROE | -11.66% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 21.82% | ||
| FCFM | 2.24% |
ROA(3y)-2.82%
ROA(5y)-0.09%
ROE(3y)-8.14%
ROE(5y)-1.42%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-13.68%
GM growth 5Y-7.41%
F-Score5
Asset Turnover0.46
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.38 | ||
| Debt/FCF | 49.84 | ||
| Debt/EBITDA | 11.05 | ||
| Cap/Depr | 61.22% | ||
| Cap/Sales | 6.78% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 90.27% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.51 | ||
| Quick Ratio | 1.93 | ||
| Altman-Z | 1.62 |
F-Score5
WACC9.31%
ROIC/WACCN/A
Cap/Depr(3y)125.99%
Cap/Depr(5y)159.79%
Cap/Sales(3y)11.57%
Cap/Sales(5y)13.39%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-61.4%
EPS 3Y-56.51%
EPS 5Y-33.48%
EPS Q2Q%-30%
EPS Next Y350.55%
EPS Next 2Y148.11%
EPS Next 3Y113.64%
EPS Next 5Y73.38%
Revenue 1Y (TTM)4.71%
Revenue growth 3Y3.1%
Revenue growth 5Y11.71%
Sales Q2Q%4.18%
Revenue Next Year8.33%
Revenue Next 2Y8.2%
Revenue Next 3Y8.33%
Revenue Next 5Y7.44%
EBIT growth 1Y-166.67%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year196.68%
EBIT Next 3Y58.17%
EBIT Next 5Y41.23%
FCF growth 1Y121.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y116.85%
OCF growth 3Y-14.78%
OCF growth 5Y1.59%